OZMOSI and Planview have partnered to link external scientific data with internal R&D planning to support pharmaceutical organisations.

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.

UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.

Sanofi has received approval from the US FDA for a supplemental biologic licence application for Tzield, allowing its use to delay stage 3 T1D onset in children as young as one year diagnosed with ...

This Durham-based facility will be AbbVie’s first manufacturing site in the state, and will become a centre of excellence for SVP production.

In global nephrology studies, aligning biology, design, operations, and interpretation across regions is essential for avoiding small missteps that could amplify through development.

MSD and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation.

Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.

The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly.

Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.